LPCN

Lipocine Inc.

3.86 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Lipocine Inc. stock is down -0.77% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.64% of the previous 10 February’s closed higher than January.

About Lipocine Inc.

Lipocine focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy.